At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 52 enrolled
Drug / intervention
aliskiren +1 moredrug
Likely dose
aliskiren 300mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Blinded, Placebo-Controlled Six Month Treatment Trial of Aliskiren to Improve Exercise Tolerance in Older Patients With Heart Failure and Normal Ejection Fraction
In Brief
A Phase 4 clinical trial evaluating aliskiren and placebo for Heart Failure. Completed, enrolled 52 participants across 1 site.
Detailed Summary
The primary objective of this study is to determine whether treatment with aliskiren (300 mg) compared to placebo will improve treadmill exercise time in older (age ≥ 55 years) patients with heart failure and normal ejection fraction (HFNEF).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure
CountriesUnited States
CollaboratorsNovartis Pharmaceuticals
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2009
First PostedSep 2009
Primary CompletionSep 2011
Study CompletionDec 2011
TodayJul 2026
First PostedSep 22, 2009
Enrollment StartJul 1, 2009
Primary CompletionSep 1, 2011
Study CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 16.8 years ago
Interventions
aliskirendrug
aliskiren 300mg qd versus placebo for 24 weeks.
placebodrug
placebo qd for 24 weeks